An increased focus on targeted therapeutics has driven rapid growth in the Highly Potent Active
Pharmaceutical Ingredients (HPAPIs) segment of the pharmaceutical industry. The surge in
antibody-drug conjugates (ADCs) boosts that forecast even further since their core active
component, the payload, is typically classified as an HPAPI.
This white paper explores the requirements and challenges of safe HPAPI containment,
highlighting the critical role CDMOs play in the production and handling of these complex
materials.
